Pharmacy leaders have welcomed reports that the UK and EU are close to agreeing a health security arrangement to share information on medicine shortages, describing the move as good news for patients.
The Company Chemists’ Association (CCA) said better intelligence-sharing could help the UK government identify potential supply problems earlier and respond more quickly. However, it warned that the proposed agreement would not resolve the underlying issues affecting the availability of medicines.
The i Paper reported on 12 November that a draft joint UK-EU statement referred to a memorandum of understanding on health security. The two sides were said to be finalising arrangements to address shortages of certain medicines, including antibiotics, ADHD treatments and epilepsy drugs.
The agreement is expected to be discussed at the UK-EU summit in Brussels on Friday, 20 November, as part of a wider package of post-Brexit arrangements. The official text has not yet been published, so the precise scope and operation of the proposed co-operation remain unclear.
CCA chief executive Malcolm Harrison said: “Any agreement that helps the UK government to identify and respond to potential medicine shortages is good news for patients.”
He added that improved information-sharing should help the government anticipate supply problems and respond more quickly, but said it would not tackle the root causes of shortages.
Harrison argued that successive governments had driven down the prices paid for medicines, particularly generic drugs. This had encouraged some manufacturers and suppliers to prioritise other international markets, he said.
He called on the government to recognise “the value and not just the cost of medicines”, arguing that investment in medicine pricing and community pharmacies was needed to make the UK a more attractive market and strengthen patient confidence.
Community pharmacies supply around 1.2 billion NHS prescription items each year, making their role central to the country's medicines supply chain.
Why is information sharing not enough to resolve shortages?
The proposed arrangement comes amid continued pressure on medicine availability and pricing. The government has granted more than 200 price concessions every month since February, with the number reaching a record 268 in September. More than 200 concessions were also reported in October, marking an eighth consecutive month above that threshold.
Mark Dayan, Brexit programme lead at the Nuffield Trust, said medicine shortages often affected several European countries at the same time. Analysis of shortages in France and the UK had highlighted the overlap, he said.
He described closer co-operation as a positive first step, adding that earlier warnings could help the UK and EU avoid competing for the same supplies when medicines were in short supply.
The proposed arrangement also comes as the EU moves ahead with its Critical Medicines Act, which was formalised by the European Council and European Parliament earlier this year. The UK is not part of the legislation, prompting concerns among pharmacy professionals that manufacturers could prioritise EU countries during periods of shortage.
Dayan has warned that the Act could potentially leave the UK at a disadvantage if suppliers favour the EU market. Whether the proposed health security agreement will give the UK any practical access to the Act's co-ordination arrangements remains unclear.
The wider question is whether better communication can translate into more reliable supplies. Earlier warnings may help governments and suppliers co-ordinate their response, but they cannot by themselves increase production or make the UK a more commercially attractive destination for manufacturers.
For the CCA, that means information-sharing needs to be accompanied by action on medicine pricing and investment in the community pharmacy network. Without addressing those pressures, the UK could continue to face supply disruption even with closer co-operation with its European neighbours.












